Key result
Intranasal losartan treatment decreased amyloid beta plaques 3.7-fold and reduced inflammatory markers in the APP/PS1 transgenic mouse model of Alzheimer Disease.
Why the study?
Does intranasal losartan reduce amyloid beta plaques and inflammation in the APP/PS1 transgenic mouse model of Alzheimer disease?
Population
APP/PS1 transgenic mouse model of Alzheimer disease
Comparison
Intranasal losartan vs Vehicle
Design
Preclinical
Follow-up
2 months
Authors
Loading...
May support intranasal ARBs for cognitive decline; leaves open translation from animal models to human AD/PD trials.
Does intranasal losartan reduce amyloid beta plaques and inflammation in the APP/PS1 transgenic mouse model of Alzheimer disease?
Effect estimate: 3.7-fold decrease
Intranasal losartan at sub-antihypertensive doses exerts neuroprotective and anti-inflammatory effects in a mouse model of Alzheimer's disease.
Danielyan et al. (2010) studied Alzheimer Disease (APP/PS1 transgenic mouse model). Intranasal losartan vs. vehicle was evaluated on Amyloid beta (Abeta) plaques (3.7-fold decrease). Intranasal losartan treatment decreased amyloid beta plaques 3.7-fold and reduced inflammatory markers in the APP/PS1 transgenic mouse model of Alzheimer Disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: